This site is intended for healthcare professionals

NICE rejects Vitrakvi to treat neurotrophic tyrosine receptor kinase fusion-positive solid tumours.- Bayer HealthCare

Read time: 1 mins
Published:20th Jan 2020
The National Institute for Health and Care Excellence (NICE) has rejected Vitrakvi (larotrectinib) from Bayer as its current price, it does not have the “potential to be cost-effective.” The guidance related to Vitrakvi being used in advanced neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children who have no satisfactory treatment options. NICE considered that cost-effectiveness calculations for the drug are “very uncertain," adding that the drug’s benefit over existing treatment options is unknown. NICE said it is difficult to know how well [Vitrakvi] works because it has not been compared in the trials with other treatments. Germany’s cost-effectiveness agency, IQWiG, also rejected Vitrakvi on insufficient data. There are around 600–700 people have solid tumours with NTRK gene fusions .
Condition: NTRK Fusion Cancers
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.